Eli Lilly (LLY) Other Non-Current Assets (2009 - 2026)

Eli Lilly (LLY) has reported Other Non-Current Assets for 18 consecutive years, with $7.2 billion the latest figure, recorded in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $7.2 billion, up 19.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.2 billion (up 19.03% YoY), and the FY2025 annual result was $7.0 billion, up 22.24% from the prior year.
• Other Non-Current Assets was $7.2 billion for Q1 2026 at Eli Lilly, up from $7.0 billion in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $7.2 billion in Q1 2026 and troughed at $4.3 billion in Q1 2022.
• Average Other Non-Current Assets over 5 years is $5.3 billion, with a median of $4.9 billion recorded in 2023.
• Year-over-year, Other Non-Current Assets climbed 4.27% in 2024 and advanced 29.03% in 2025.
• Over 5 years, Other Non-Current Assets stood at $4.3 billion in 2022, then grew by 15.05% to $5.0 billion in 2023, then advanced by 14.63% to $5.7 billion in 2024, then grew by 22.24% to $7.0 billion in 2025, then advanced by 3.42% to $7.2 billion in 2026.
• Per Business Quant data, the three most recent Other Non-Current Assets figures were $7.2 billion in Q1 2026, $7.0 billion in Q4 2025, and $6.4 billion in Q3 2025.